169 related articles for article (PubMed ID: 38523528)
1. Patterns of B-cell lymphocyte expression changes in pre- and post-malignant prostate tissue are associated with prostate cancer progression.
Sadasivan SM; Loveless IM; Chen Y; Gupta NS; Sanii R; Bobbitt KR; Chitale DA; Williamson SR; Rundle AG; Rybicki BA
Cancer Med; 2024 Mar; 13(6):e7118. PubMed ID: 38523528
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer.
Flammiger A; Bayer F; Cirugeda-Kühnert A; Huland H; Tennstedt P; Simon R; Minner S; Bokemeyer C; Sauter G; Schlomm T; Trepel M
APMIS; 2012 Nov; 120(11):901-8. PubMed ID: 23009114
[TBL] [Abstract][Full Text] [Related]
3. Tumor infiltrating B-cells are increased in prostate cancer tissue.
Woo JR; Liss MA; Muldong MT; Palazzi K; Strasner A; Ammirante M; Varki N; Shabaik A; Howell S; Kane CJ; Karin M; Jamieson CA
J Transl Med; 2014 Jan; 12():30. PubMed ID: 24475900
[TBL] [Abstract][Full Text] [Related]
4. Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer.
Rybicki BA; Rundle A; Kryvenko ON; Mitrache N; Do KC; Jankowski M; Chitale DA; Trudeau S; Belinsky SA; Tang D
Int J Cancer; 2016 Jun; 138(12):2884-93. PubMed ID: 26860439
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer.
Ryan ST; Zhang J; Burner DN; Liss M; Pittman E; Muldong M; Shabaik A; Woo J; Basler N; Cunha J; Shalapour S; Estrada MV; Karin M; Messer K; Howell S; Kane CJ; Jamieson CAM
J Transl Med; 2020 May; 18(1):214. PubMed ID: 32466781
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate.
Fujii T; Shimada K; Asai O; Tanaka N; Fujimoto K; Hirao K; Konishi N
Pathobiology; 2013; 80(3):119-26. PubMed ID: 23328608
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. The interplay of growth differentiation factor 15 (GDF15) expression and M2 macrophages during prostate carcinogenesis.
Sadasivan SM; Chen Y; Gupta NS; Han X; Bobbitt KR; Chitale DA; Williamson SR; Rundle AG; Tang D; Rybicki BA
Carcinogenesis; 2020 Aug; 41(8):1074-1082. PubMed ID: 32614434
[TBL] [Abstract][Full Text] [Related]
10. Benign prostate glandular tissue at radical prostatectomy surgical margins.
Odisho AY; Washington SL; Meng MV; Cowan JE; Simko JP; Carroll PR
Urology; 2013 Jul; 82(1):154-9. PubMed ID: 23522995
[TBL] [Abstract][Full Text] [Related]
11. SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy.
Faisal FA; Kaur HB; Tosoian JJ; Tomlins SA; Schaeffer EM; Lotan TL
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):552-559. PubMed ID: 30850708
[TBL] [Abstract][Full Text] [Related]
12. Residual prostatic tumour in the surgical bed following radical prostatectomy in organ-confined prostate cancer: possible prognostic significance.
Valotto C; Falconieri G; Pizzolitto S; Cerruto MA; Brondani G; De Gobbi A; Zattoni F
Arch Ital Urol Androl; 2011 Jun; 83(2):78-82. PubMed ID: 21826879
[TBL] [Abstract][Full Text] [Related]
13. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral inflammation is associated with more aggressive prostate cancer.
Klink JC; Bañez LL; Gerber L; Lark A; Vollmer RT; Freedland SJ
World J Urol; 2013 Dec; 31(6):1497-503. PubMed ID: 23546767
[TBL] [Abstract][Full Text] [Related]
16. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte-to-monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy.
Cho MC; Yoo S; Choo MS; Son H; Jeong H
Prostate; 2021 Dec; 81(16):1278-1286. PubMed ID: 34516662
[TBL] [Abstract][Full Text] [Related]
18. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
19. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
Zhou M; Shah R; Shen R; Rubin MA
Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
[TBL] [Abstract][Full Text] [Related]
20. The effect of hexanic extract of Serenoa repens on prostatic inflammation: results from a randomized biopsy study.
Gravas S; Samarinas M; Zacharouli K; Karatzas A; Tzortzis V; Koukoulis G; Melekos M
World J Urol; 2019 Mar; 37(3):539-544. PubMed ID: 30027406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
